SCHEMBL4468865

SCHEMBL4468865

CCC(O)c1oc(-c2ccc(C(F)(F)F)cc2)nc1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 6/20 0.48
PPARG P37231 5/20 0.48
PPARA Q07869 4/20 0.45
IKBKB O14920 1/20 0.45
PTPN1 P18031 5/20 0.42
LMNA P02545 2/20 0.41
THRB P10828 1/20 0.41
PDE2A O00408 1/20 0.40
UTRN P46939 1/20 0.38
MEN1 O00255 2/20 0.38
MAPT P10636 2/20 0.38
CRHBP P24387 2/20 0.38
KMT2A Q03164 2/20 0.38
CRHR2 Q13324 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
NOTUM Q6P988 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6000002 0.90 PPARD (0.48) PPARDPPARGPPARAIKBKBPTPN1
SCHEMBL4464216 0.88 PPARD (0.46) PPARDPPARGPPARAIKBKBPTPN1
SCHEMBL5216456 0.85 PTPN1 (0.52) PPARDPPARGPPARAIKBKBPTPN1
SCHEMBL4475278 0.85 PPARD (0.45) PPARDPPARGPPARAIKBKBPTPN1
SCHEMBL4464845 0.85 PPARD (0.48) PPARDPPARGPPARAIKBKBPTPN1
SCHEMBL4468828 0.82 PPARD (0.46) PPARDPPARGPPARAIKBKBPTPN1
SCHEMBL1980612 0.82 PPARG (0.53) PPARDPPARGPPARAIKBKBPTPN1
SCHEMBL3742873 0.82 PPARD (0.49) PPARDPPARGPPARAIKBKBPTPN1
SCHEMBL4484951 0.81 PTPN1 (0.47) PPARDPPARGPPARAIKBKBPTPN1
SCHEMBL11959550 0.79 PPARD (0.49) PPARDPPARGPPARAIKBKBPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528160-B2 Fused heterocyclic derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2009-05-05 US disclosed
US-7528160-B2 Fused heterocyclic derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2009-05-05 US disclosed
US-7528160-B2 Fused heterocyclic derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2009-05-05 US disclosed
EP-1480640-B1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS LILLY CO ELI (US) 2007-08-15 EP disclosed
EP-1480640-B1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS LILLY CO ELI (US) 2007-08-15 EP disclosed
US-7153878-B2 Peroxisome proliferator activated receptor modulators ELI LILLY AND COMPANY (US) 2006-12-26 US disclosed
US-20060217374-A1 Fused heterocyclic derivates as ppar modulators ELI LILLY AND COMPANY 2006-09-28 US disclosed
US-20060166983-A1 Indole derivatives as ppar modulators ELI LILLY AND COMPANY 2006-07-27 US disclosed
US-20050107449-A1 Peroxisome proliferator activated receptor modulators ELILILLY AND COMPANY 2005-05-19 US disclosed
EP-1480640-A1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-12-01 EP disclosed
WO-2003072100-A1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166983-A1 Indole derivatives as ppar modulators PPARA, PPARD, PPARG PPARD 2/4885PPARG 3/4885PPARA 1/4885
US-20050107449-A1 Peroxisome proliferator activated receptor modulators PPARG, PPARA, PPARD PPARD 3/4885PPARG 1/4885PPARA 2/4885
US-20060217374-A1 Fused heterocyclic derivates as ppar modulators PPARG, PPARA, PPARD PPARD 3/4885PPARG 1/4885PPARA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.